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Abstract
Dipyrone (metamizole), acting through its main metabolites 4-methyl-amino-antipyrine and 4-amino-antipyrine, has established
analgesic, antipyretic, and spasmolytic pharmacological effects, which are mediated by poorly known mechanisms. In rats,
intravenously administered dipyrone delays gastric emptying (GE) of liquids with the participation of capsaicin-sensitive afferent
fibers. This effect seems to be mediated by norepinephrine originating from the sympathetic nervous system but not from the
superior celiac-mesenteric ganglion complex, which activates b2-adrenoceptors. In rats, in contrast to nonselective non-
hormonal anti-inflammatory drugs, dipyrone protects the gastric mucosa attenuating the development of gastric ulcers induced
by a number of agents. Clinically, it has been demonstrated that dipyrone is effective in the control of colic-like abdominal pain
originating from the biliary and intestinal tracts. Since studies in humans and animals have demonstrated the presence of b2-
adrenoceptors in biliary tract smooth muscle and b2-adrenoceptor activation has been shown to occur in dipyrone-induced
delayed GE, it is likely that this kind of receptors may participate in the reduction of smooth muscle spasm of the sphincter of
Oddi induced by dipyrone. There is no evidence that dipyrone may interfere with small bowel and colon motility, and the clinical
results of its therapeutic use in intestinal colic appear to be due to its analgesic effect.
Key words: Dipyrone; Gastric emptying; Gastric mucosa; Sphincter of Oddi; Intestinal Motility; Adrenergic receptors
Introduction
Antipyrine (phenazone), a compound with a relatively
simple structure synthesized around 1880, has been used
as an antipyretic and analgesic agent (1,2). This drug is
metabolized by mitochondrial enzymes in the liver and
generates as a main product 4-hydroxyantipyrine and its
conjugates, which are eliminated in the urine (2).
Further modifications of the antipyrine molecule aiming
at improving its analgesic and antipyretic properties gave
origin to various pharmaceuticals, such as aminophena-
zone (aminopiryne or amidopyrine), propyphenazone, dipy-
rone (metamizole), and phenylbutazone (1).
More recently, other pyrazolone derivatives have been
synthesized and have experimentally demonstrated effec-
tive analgesic, anti-inflammatory, antiplatelet, and anticon-
vulsant activities, among other effects (3).
Clinically, dipyrone shows powerful analgesic, antipy-
retic, and antispasmodic effects, whereas its anti-inflamma-
tory activity is considered irrelevant (4).
Dipyrone, as the most popular pyrazolone derivative,
is a drug extensively employed therapeutically in some
countries, whereas its use has been banned or restricted
in others due to its possible undesired and dangerous
reactions, such as agranulocytosis (4). Dipyrone is generally
regarded as a pro-drug that generates in vivo larger
metabolites, such as 4-methyl-amino-antipyrine (MAA),
4-amino-antipyrine (AA), 4-acetyl-amino-antipyrine (AAA),
and 4-formyl-amino-antipyrine (FAA) (1,4). Its pharma-
cological effects are attributed to the active metabolites
MAA and AA (1,4,5). In humans and rats, non-enzymatic
hydrolysis of dipyrone generates MAA, which is subse-
quently metabolized in the liver under the action of
cytochrome P450 subfamilies (6,7).
In the present text, detailed information is provided
regarding the mechanisms of dipyrone pharmacological
actions, and the effects on gastrointestinal motility, gastric
mucosa, and the spasmolytic property of this drug.
Material and Methods
For the present review, we analyzed papers available in
the PubMed database up to December 2017, using the
following key words, separately or in combination: dipy-
rone (metamizole), mechanisms, gastrointestinal motility,
gastric emptying, gastric mucosa, colic pain, sphincter of
Oddi, sympathetic nervous system, adrenergic recep-
tors, cyclooxygenases (COXs). Studies in which dipyrone
effects were assessed in combination with other drugs
(composite preparations) were not included.
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Although dipyrone is known as a powerful analgesic
and antipyretic agent, the identification of the mechanisms
involved in these effects lags considerably behind
the advances observed regarding other drugs with similar
properties.
Recent work has suggested possible mechanisms
involved in the triggering of experimental endotoxic (lipopo-
lysaccharide, LPS) fever by the rapid peripheral production
of prostaglandin E2 (PGE2) followed by maintenance
of its synthesis (8). This generates a pyrogenic message
that reaches the central nervous system (CNS) through
mechanisms involving both neuronal pathways (afferent
pathway of the vagus nerve) and humoral pathways (8).
Evidence obtained in experimental models has shown
that the dipyrone MAA metabolite inhibits both PGE2-
dependent and -independent fever, whereas AA blocks
PGE2-dependent fever (9,10).
Dipyrone is currently classified as a non-opioid anal-
gesic, although for a long time it was incorrectly included
in the group of non-steroidal anti-inflammatory drugs
(NSAID) (11). The mechanisms involved in its analgesic
effect are not clearly understood and controversial results
have been often reported.
Inhibition of cyclooxygenase 3 (COX-3), a variant of
COX-1, by analgesic/antipyretic drugs with low anti-inflam-
matory activity such as dipyrone (including its MAA
metabolite) and antipyrine may possibly be the primary
CNS mechanism for the reduction of pain (12).
In addition to COX-3 inhibition, both the opioidergic and
cannabinoid systems may be involved in the analgesic
effect of the drug, or rather of its active metabolites (11).
Studies in mice suggest the participation of endogenous
cannabinoid and vanilloid systems (5,13,14) with activation
of cannabinoid receptor type 1 (CB1) and transient receptor
potential vanilloid 1 (TRPV1) receptors, respectively, in the
periaqueductal-gray rostral ventromedial medulla axis of
the CNS (14). In this animal model, parenterally adminis-
tered dipyrone and antipyrine, but not MAA, blocked the
transient receptor potential ankyrin 1 (TRPA1) channel. This
receptor is expressed by peripheral sensory neurons with
cell bodies in the dorsal root ganglia, functioning as antago-
nists of this channel, which, when activated, have a hyper-
algesic nociceptive effect (15). On the other hand, another
study concluded that arachidonoyl metabolites, which
depend on the action of the fatty acid amide hydrolase,
and cannabinoid receptors do not participate in the pharma-
cological effects of this drug under non-inflammatory
conditions (16). In addition, a study also conducted in mice
suggested that, in acute pain tests, cannabinoid CB1
receptors do not participate in the antinociceptive effect
of dipyrone administered intraperitoneally, although the
participation of these receptors in other painmodels (neuro-
pathy, inflammation, etc.) or in different routes of administra-
tion of the drug was not ruled out (17).
The involvement of the descending spinal pathways in
the analgesic effect of dipyrone is controversial. One
study concluded that the descending spinal adrenergic
(a2-adrenoceptors) and serotonergic (5-HTreceptors) path-
ways do not participate in this effect (18). More recently,
however, evidence has been reported that various sub-
types of serotonergic receptors (5-HT2a, 5-HT3, and
5-HT7-serotonergic) and adrenergic subtypes (a1, a2, b-
adrenergic receptors) mediate the antinociceptive effect of
dipyrone (19).
The central analgesic effect of this drug has been
contested in a rat model of inflammatory pain (intraplantar
injection of l-carrageenan), thus suggesting that its
peripheral action is not opioid-dependent (20).
It has been found in rats that thirty minutes after local
administration of dipyrone the anti-hyperalgesic effect is
associated to the activation of neuronal CB1 receptors
induced by the AA metabolite and MAA-induced cGMP
activation, with opening of the neuronal KATP channel (21).
In contrast, another study also conducted in rats concluded
that cannabinoid receptors are not involved in the periph-
eral antinociception induced by dipyrone (22). However, in
the latter study the antinociceptive effect was evaluated
5min after local (paw) administration of dipyroneand15min
after local application of the CB1 and CB2 cannabinoid
receptor antagonists in a model of hyperalgesia with
previous local application of PGE2. Because of the need to
generate active metabolites at the site of dipyrone applica-
tion (23), the short time between application and evaluation
of the effect in this study raises the possibility that the
required local concentrations of these metabolites were not
reached, thus making debatable the interpretation of this
study and of others that used the same model.
Effects on the stomach
Gastric motor activity
More than 30 years ago it was observed that antipyrine
per os (po) (100 mg/kg) and intravenous (iv) dipyrone
(50, 250, and 1250 mg/kg) delay gastric emptying (GE) in
rats (24,25).
Using saline as the test meal, this phenomenon was
confirmed after iv administration of equimolar doses (240
mmol/kg) of dipyrone (80 mg/kg) and antipyrine (45.17 mg/
kg), and was amplified with the inclusion of the AA metab-
olite (48.77 mg/kg) (26–29). Additional experiments con-
ducted in an attempt to identify the mechanisms involved
have shown that: 1) the iv effect of the three drugs was
dose dependent (26–29); 2) at the dose of 240 mmol/kg a
maximum effect occurred 10 min after antipyrine adminis-
tration and during the first hour after the administration of
dipyrone and AA (26–29); 3) dipyrone was the only drug
that caused delayed GE when applied by the intracerebro-
ventricular (icv) route (26–29); 4) electrolytic lesion of the
paraventricular nucleus (PVN) of the hypothalamus
abolished the iveffect of dipyrone (26);5) subdiaphragmatic
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vagotomy significantly reduced the effect of the three drugs
(26–29); 6) dipyrone and antipyrine administered by the
parenteral route increased gastric compliance (28); 7)
icv administration of baclofen, a GABAB receptor agonist,
blocked the parenteral effect of dipyrone, AA, and anti-
pyrine, and of dipyrone administered icv (27–29); 8) appar-
ently, there is no involvement of nitric oxide in the iv effect
of dipyrone, opioids, or dopamine receptors (30).
Treatment of rats with capsaicin during the neonatal
period (31), a procedure that causes the degeneration of
non-myelinated peripheral afferent neurons (32,33), results
in full blockade of the effect of the three drugs (dipyrone,
AA, and antipyrine) on GE when administered iv, but not
of the effect of icv dipyrone. This finding suggests that
neurotoxin-sensitive afferent fibers carry the peripheral
stimulus involved in GE delay. In addition, it was reported
that the selective blockade of CCK1 or 5-HT3 receptors
contained in these fibers, which, when activated during the
digestive phase delays GE, did not modify the effect of the
pyrazolone derivatives (31).
Capsaicin-sensitive afferent fibers of the common
hepatic branch of the vagus project towards the rat liver (34).
Since dipyrone metabolites are processed by cytochrome
P450 in therat liver (7), theeffectof thisdrugmayhypothetically
stimulate these fibers through unknown mechanisms. How-
ever, results obtained with the parenteral administration
of dipyrone,AA,andantipyrine to ratspreviously submitted
to section of the hepatic branch of the vagus indicated
that the fibers that pass through this branch are not
involved in the mechanisms resulting in delayed GE (35).
Under non-physiological experimental conditions, there
is evidence that the adrenergic system is involved in
delayed GE in rats (36–40). The possibility of the partici-
pation of this system in the effect of these pyrazolone
derivatives on GE was investigated and it was found that
acute iv adrenergic blockade with guanitidine or iv pretreat-
mentwithpropranolol (anon-selectiveb-adrenergicantago-
nist) abolished the effect of dipyrone and antipyrine on GE
(41). The same procedure significantly reduced, but did
not abolish, the effect of the AA metabolite. Propranolol
administered icv did not alter the parenteral effect of the
three drugs. These results suggest the participation of the
adrenergic system in the delayed GE phenomenon by
activation of b1- and/or b2-adrenergic receptors through the
sympathetic nervous system (SNS).
Bilateral ablation of the adrenal glands, but not of the
gland medulla, enhances the emptying of a liquid saline
meal in rats (42). Although evidence of the participation of
the SNS in the effect of the three drugs was significant,
the possibility that part of the neurotransmitter might
originate from the medulla of the adrenal glands could not
be ruled out. However, bilateral enucleation of the adrenal
medulla did not modify significantly the effect of the drugs
on GE (Vinagre AM, Collares EF, unpublished results),
thus supporting the hypothesis that the neurotransmitter
may originate from the peripheral endings of the SNS.
b1- and b2-adrenergic receptors have been identified
in the gastric mucosa and antrum muscle in rats (43),
together with elevated levels of b3-adrenoceptor mRNA
expression in themuscle fibers of the gastric fundus and the
pylorus (44). A recent study using previous parenteral
administration of selective b1-, b2-, or b3-adrenergic antago-
nists suggested that b2-adrenoceptor activation occurs in
the GE delay induced by pyrazolone derivatives (45),
while the b2-adrenergic antagonist butoxamine completely
blocked the effect of dipyrone and antipyrine on GE. In
addition, this antagonist significantly reduced, but did not
abolish, the effect of the AA metabolite, as observed in
the previous study (41) using blockade with guanidine or
pretreatment with propranolol. These results indicate that:
1) part of the effect of dipyrone on GE is likely to be due to
activation of the b2-adrenoceptor by the AA metabolite;
2) a substantial component of the mechanism involved
in the effect of AA (at a dose of 240 mmol/kg) is unknown.
The same study (45) also ruled out the involvement of
the superior celiac-mesenteric ganglion complex of the
SNS, so that the peripheral origin of the adrenergic neuro-
transmitter continues to be unknown. Based on available
information, at least three possibilities may be suggested
for the neurotransmitter origin: the splanchnic ganglia of
the prevertebral ganglion chain, the sympathetic paraver-
tebral ganglion chain for the distal part of the thorax, or the
noradrenergic efferent fibers of the vagus nerve (45–49).
Gastric mucosa
Amongst the well-known complications of the thera-
peutic use of NSAID, especially the non-selective COX
inhibitors, are the development of gastric mucosal ulcers
and changes in gastric motility (50). Considering indo-
methacin (a non-selective COX inhibitor) as themainmodel
of injury to thegastricmucosa inducedbyNSAID inanimals,
a recent review on pathogenesis (50) reached the follow-
ing conclusions: 1) concomitant inhibition of COX-1 (a
constitutive isoenzyme) and COX-2 (an induced isoen-
zyme) is needed for the development of gastric mucosa
injuries; 2) COX-1 inhibition and the consequent PGE2
deficiency may be responsible for gastric hypermotility
which, in turn, causes vascular injury, microcirculation
disorders and reduced mucosal blood flow. Gastric hyper-
motilitymay play a primary role in the development of gastric
injury, occurring before later phenomena also involved in
injury, such as increased neutrophil migration; 3) prosta-
glandins (PGs) produced by COX-2 induction counter-
balance the deleterious effect of COX-1 inhibition alone; 4)
the mechanism through which COX-1 inhibition alone
induces COX-2 expression is unknown.
Contrary to the participation of gastric hypermotility
in mucosal injury is the observation that non-selective
COX inhibition by intragastric indomethacin delayed liquid
GE in an animal model and reduced gastric tonus (51).
This precedes the development of mucosal lesions and
neutrophil infiltration, thus suggesting that there is no
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relationship between abnormal gastricmotility andmucosal
injury (51). Differences regarding stomach motor activity
may be possibly due to the route of indomethacin admin-
istration, with the subcutaneous route having a parenteral
effect (50) and the intragastric route having a local effect
(51). One study favoring this interpretation showed that
selective iv inhibition of COX-2 by valdecoxib increased
gastric tonus in rats (52), suggesting that the abnormal
gastric motility detected when indomethacin was adminis-
tered by the parenteral route (50) may have been due to a
predominant inhibition of COX-2.
Dipyrone, in contrast to the non-selective NSAIDs of
the COXs, has a distinct effect on the gastric mucosa in
humans and animals. Prolonged po treatment (14 days) of
rats with dipyrone (60mg  kg-1 12 h-1) did not cause gastric
ulcers, did not affect COX-1 expression, and did not induce
COX-2 expression in the gastric mucosa (53). Orogastric
administration of higher doses (1000 mg/kg) induced only
few injuries to the gastric mucosa, which does not seem to
relate to the significant reduction of PGE2 production,
but is associated to inhibition of the NO/cGMP pathway
and cNOS activity, which are known as important mucosal
protective factors (54). In vitro, in contrast to the classical
COX inhibitors, dipyrone and its MAA and AA metabolites
apparently inhibit COX activity by either sequestering
the radicals that initiate this enzyme catalytic activity or
reducing the COX protein oxidative state. This indicates a
distinctmechanismof action thatmayexplain theweakanti-
inflammatory effect of the drug (55).
Acute intraperitoneal (ip) pretreatment of rats with a
single dose of dipyrone (5, 25, and 100 mg/kg) attenuated
the development of ulcers induced by histamine and
diethyldithiocarbamate, but not of those induced by stress.
In control animals with no gastric ulcer, 5 mg/kg ip dipyrone
increased PGE2 in the gastric contents (56). The pro-
tective effect of dipyrone was considered to be due to the
increased synthesis and/or release of gastric mucus and
to the increased gastric content of PGE2 (56). In addition,
3-day ip pretreatment with dipyrone (25, 50, and 100mg/kg)
reduced both the ulcer index and mucus secretion in
rats with gastric ulcer induced by stress and diethyldithio-
carbamate (57).
A significant increase in the risk of upper digestive
bleeding induced by dipyrone, although twice lower than
that of aspirin, has been identified in adult humans (58).
Dipyrone administered po to healthy volunteers for two
weeks (1.5 g/day) had no effect on the gastric or duodenal
mucosa, with discrete damage being observed only with a
higher dose (3 g/day) (59).
Fromanother viewpoint, it iswell known that, in humans,
gastric-secreted acid and pepsin comprise an important
factor in the genesis, maintenance, or worsening of the
upper digestive tract mucosal injury, such as those found in
erosive esophagitis due to gastroesophageal reflux, gastric
and, especially, duodenal peptic ulcers andNSAID-induced
lesions (60). No information, however, was found in the
literature regarding the effect of dipyrone on the production
of these twocomponentsof gastric secretion.Nevertheless,
it is possible to speculate that absence of gastric ulcers
associated to the use of dipyrone may be due to the inter-
ference of the drug in the regulation of gastric secretion.
Thus, using an in vivo model for the study of gastric
secretion in rats with iv administration of several drugs,
isoprenaline (isoproterenol), a b1- b2-adrenergic agonist,
inhibited the acid secretion induced by pentagastrin, an
effect that was abolished by the administration of propra-
nolol or butoxamine (61). In contrast, an in vitrostudywith an
isolated stomach preparation showed that propranolol
inhibited the enhancement of acid secretion induced by
isoprenaline, a phenomenon thatwasnot affectedby butox-
amine (61). These results lead to the conclusion that
isoprenaline has an indirect (parenteral) inhibitory effect
and a direct stimulatory effect on gastric acid secretion in
rats, both involving activation of b-adrenoceptors (61).
Since b-adrenoceptor activation by the parenteral route
inhibits gastric acid secretion, itmay be concluded indirectly
that dipyrone, by activating these receptors in the stomach
via the SNS, may have a protective effect on the gastric
mucosa. However, findings from other studies did not
support this interpretation. In three models of ulceration
induced by ethanol, indomethacin, and stress in awake
rats, po or ip pretreatment with propranolol (62) and butox-
amine (63) prevented injury to the gastric mucosa, an
effect attributed to reinforcement of the mucosal barrier by
b-adrenergic antagonists due to the preservation of mucus-
producing cells and of mucosal integrity. In anesthetized
rats, using the same models on an ex-vivo gastric chamber
preparation, butoxamine administered intragastrically or
ip did not change the production of pepsin or acid, indicating
that the antiulcerogenic action of this b2-adrenergic anta-
gonist was not related to a reduced secretion of these
components (63).
In conclusion, the mechanisms by which dipyrone, in
contrast to nonselective NSAIDs, has a protective effect on
the gastric mucosa are still unclear.
Effect on intestinal motility
Studies using in vitro preparations of smooth muscle
have reported controversial results regarding the spasmo-
lytic activity of dipyrone (64–68). These conflicting results
maybe related to the fact thatdipyrone isapro-drug thatmay
not have a direct effect on the muscle in vitro but acts
indirectly through itsmetabolites,MAA in particular, which is
generated by the drug hydrolysis (23). Ergün et al. (69)
defined the following factors as being important for the
in vitro effects of dipyrone: occurrence of non-enzymatic
drug hydrolysis, local drug concentrations, and conditions
related to pH, temperature and period of incubation of
the muscle preparation in the organ bath. All these condi-
tions must be strictly controlled in order to obtain reliable
results.
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Little information is available about the action of dipyr-
one on intestinal motility. Small bowel peristalsis of guinea
pig intestine is not blocked when exposed in vitro to
10–100 mM dipyrone in a bath for 60 min (70). In contrast,
at higher concentrations (100–500 mM), the drug had a
myogenic spasmolytic effect for 30 min in the ileum (71).
On the other hand, dipyrone (50 and 250 mg/kg) adminis-
tered in vivo to rats did not change the intestinal transit (25),
and the drug had no effect on experimentally induced
contractions of the cecum of ponies (72), and on the jejunal
or colonic (pelvic flexure) motility of these animals (73).
In the awake opossum, without the addition of any other
active principle, the drugwas not able to break themigrating
motor complex (MMC) cycle (74).
Whether the drug has or not a spasmolytic action on
intestinal colic is inconclusive, since experimental studies
on animals have suggested that the positive clinical
results observed in humans and animals may be due to its
analgesic property.
Effect on the biliary tract
Sphincter of Oddi dysfunction may manifest clinically
by recurrent abdominal pain of the "biliary type" and/or
episodes of acute pancreatitis, with abnormal motility of the
sphincter and a significant increase in its basal pressure
having been identified (75). In this condition, dipyrone was
proven more effective in controlling acute biliary colic pain
than opioids or pure spasmolytic drugs (76). However, a
systematic review and meta-analysis found that NSAIDs
were more effective in both control of biliary colic and
prevention of potential progression to cholelithiasis than
opioids, spasmolytic drugs, or dipyrone, probably because
of the diversity of their pharmacological actions, locally
and in the CNS (77). A more recent meta-analysis that
did not include dipyrone also indicated that NSAIDs were
superior to placebo and spasmolytic drugs, but not to
opioids, in the control of biliary colic, additionally indicating a
reduction in the frequency of complications related to the
biliary tract (78).
Dipyrone was found to reduce the tonus of the sphincter
ofOddi inhumans,whichpossibly indicatesanothermecha-
nism of action on biliary colic, in addition to the analgesic
effect (79). Conversely, dipyrone did not change the biliary
pressure or the sphincter of Oddi myoelectric activity in
the non-sedated opossum (74). No information was found
in the literature about the effect of the drug on the biliary
pathways in rats.
The sphincter of Oddi in species such as the opossum,
the guinea pig, and the rabbit has different anatomical and
functional motor characteristics than those of humans (80).
This is not the case for carnivore animals (dogs and cats), in
which the structure and function of the sphincter of Oddi
were found to be similar to those of humans (80,81).
In dogs and cats, the sphincter of Oddi is under direct
adrenergic control from thesympathetic plexusandganglia,
with the participation of adrenergic axons of the vagus
beingapparentlyquestionable (82). Inaddition, sympathetic
stimulation causes relaxation of the gallbladder through
a direct effect, which was found in dogs and cats and in
humans as well (83).
Adrenergic fibers were found to partially mediate relax-
ation of the isolated gallbladder of dogs, with a significant
component of this effect depending on non-cholinergic,
non-adrenergic neurotransmitters (nitric oxide, intestinal
vasoactive peptide, and carbon monoxide) (84).
In an isolated preparation of the sphincter of Oddi of
cats, it was demonstrated that a-adrenoceptor activation
promotes contraction, whereas activation of b-adrenocep-
tors promotes relaxation (85). In anesthetized cats, the
sphincter of Oddi tonus increased in vivo due to the activa-
tion of a-adrenoceptors and decreased with the activation
of b-adrenoceptors probably with the involvement of the
b2-adrenergic subtype (86). In addition, in anesthetized
cats, the activation of the b2-adrenoceptor induced relaxa-
tion of the sphincter of Oddi, a phenomenon antagonized
by propranolol and by the selective blockade of the
b2-adrenergic receptor (87).
Although the use of results from experiments in animals
to interpret what occurs in humans is limited, a reasonable
amount of information allows the speculation that the
activation of b2-adrenoceptors by metabolites of dipyrone
(the same involved in delaying GE in rats) may contribute,
at least in part, to the drug spasmolytic effect on biliary colic.
In this clinical situation, this effect may occur in addition to
the analgesic property of the drug. However, the demon-
stration of the participation of the b2-adrenergic subtype
in the effect of dipyrone in humans may be questioned,
taking into account that the selective adrenergic antago-
nists currently available also block b-adrenoceptors in the
respiratory apparatus, provoking bronchospasm (88).
Relationship between the antinociceptive
and antispasmodic effects of dipyrone
A few studies have examined the antinociceptive effect
of dipyrone in rats (20,21). Hernández-Delgadillo et al. (89)
and Silva-Moreno et al. (90) evaluated this effect using
extremely high doses of iv dipyrone, i.e., 7.5 and 5 times
higher, respectively, than those employed in studies of the
effect of the drug on GE of liquids in rats (26–31,35,41,45).
Rupp et al. (25), in a study of the effect of dipyrone on GE in
rats, used 1250 mg/kg iv as the maximum dose. However,
the authors detected a significant delay of GE with a lower
dose (50 mg/kg). In our first observation (26), the delay of
GE was already significant with a dose of 40 mg/kg. In
subsequent studies, the dose of 80 mg/kg was used as
reference.The relationshipsbetween theeffectsofdipyrone
on GE of rats and its antinociceptive influence is therefore
unknown, and whether this is dependent on dosage is
uncertain. On the basis of the dose-response curves of the
two mentioned studies (89,90), we observed that the dose
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of 80 mg/kg is lower than the lower limit of the curve of the
antinociceptive effect (percent of maximum possible effect)
of this drug in rats. Although this is a rough interpretation,
it may indicate that there is no relationship between the
two effects.
Unknown effects on the digestive tract
We did not find information in the literature available on
the effect of dipyrone on the motor activity of the stomach
in humans. In addition, there is no information on the effect
of the drug on the motor activity of other parts of the gas-
trointestinal tract, such as the esophagus and the lower
esophageal sphincter, the pylorus, or the internal anal
sphincter, both in humans or animals.
Research proposals
The available information regarding the effect of pyra-
zolone derivatives on GE in rats is limited, which indicates
the need of further studies in order to clarify several points
that might help understand the spasmolytic effect of
dipyrone on the digestive tract. Among them, the following
points should be clarified: 1) degree of participation of
the MAA and AA metabolites and others in the effect of
dipyrone; 2) mechanism(s) by which pyrazolone deriva-
tives activate the capsaicin-sensitive afferent pathways;
3) mechanism(s) additional to the activation of the b2-
adrenoceptor mediating the effect of the AA metabolite
delaying GE; 4) origin of the norepinephrine mediator in the
SNS; 5) participation of the PVN in the integration between
the spinal and/or vagal afferent pathways; 6) the efferent
pathways of the vagus (adrenergic) and theSNS involved in
the various effects of dipyrone.
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